title: Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia.
authors.forename: Michael
authors.initials: M
authors.lastname: Doubek
authors.forename: Martin
authors.initials: M
authors.lastname: Trbušek
authors.forename: Jitka
authors.initials: J
authors.lastname: Malčíková
authors.forename: Yvona
authors.initials: Y
authors.lastname: Brychtová
authors.forename: Jana
authors.initials: J
authors.lastname: Smardová
authors.forename: Jana
authors.initials: J
authors.lastname: Lochmanová
authors.forename: Anna
authors.initials: A
authors.lastname: Panovská
authors.forename: Hana
authors.initials: H
authors.lastname: Skuhrová Francová
authors.forename: Marek
authors.initials: M
authors.lastname: Mráz
authors.forename: Boris
authors.initials: B
authors.lastname: Tichý
authors.forename: Ludmila
authors.initials: L
authors.lastname: Sebejová
authors.forename: Veronika
authors.initials: V
authors.lastname: Navrkalová
authors.forename: Karla
authors.initials: K
authors.lastname: Plevová
authors.forename: Petr
authors.initials: P
authors.lastname: Kuglík
authors.forename: Jiří
authors.initials: J
authors.lastname: Mayer
authors.forename: Sárka
authors.initials: S
authors.lastname: Pospíšilová
mesh_terms: D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002872:Chromosome Deletion; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D012189:Retrospective Studies; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D016159:Tumor Suppressor Protein p53; D000074323:Alemtuzumab